Evidence for roles of κ-opioid and NMDA receptors in the mechanism of action of ibogaine

Brain Research

Volumn 749, Issue 2, 1997, Pages 340-343

  Glick, Stanley D ^a   Maisonneuve, Isabelle M ^a   Pearl, Sandra M ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

opioid receptor; addiction; drug self administration; ibogaine; in vivo microdialysis; morphine; N methyl D aspartate receptor; noribogaine

Indexed keywords

DOPAMINE; IBOGAINE; KAPPA OPIATE RECEPTOR; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORBINALTORPHIMINE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG SELF ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CORPUS STRIATUM; DOPAMINE; FEMALE; IBOGAINE; MORPHINE; MOTOR ACTIVITY; N-METHYLASPARTATE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, KAPPA; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 0031041783     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)01414-X     Document Type: Article

References (21)

1. Cappendijk, S.L.T. and Dzoljic, M.R., Inhibitory effects of ibogaine on cocaine self-administration in rats, Eur. J. Pharmacol., 241 (1993) 261-265.
2. DeCoster, M.A., Conover, J.R., Hunter, J.C. and Tortella, F.C., The neuroprotective kappa-opioid CI-977 alters glutamate-induced calcium signaling in vitro, Neuroreport, 5 (1994) 2305-2310.
3. Deecher, D.C., Teitler, M, Soderlund. D.M., Bornmann, W.G., Kuehne. M.E. and Glick, S.D., Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies, Brain Res., 571 (1992) 242-247.
4. Glick, S.D., Kuehne, ME., Raucci, J., Wilson, T.E., Larson, T.D., Keller, R.W. and Carlson, J.N., Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum, Brain Res., 657 (1994) 14-22.
5. Glick, S.D., Pearl, S.M., Cai, J. and Maisonneuve, I.M., Ibogaine-like effects of noribogaine in rats. Brain Res., 713 (1996) 294-297.
6. Glick, S.D., Rossman, K., Steindorf, S. and Carlson, J.N., Effects and aftereffects of ibogaine on morphine self-administration in rats, Eur. J. Pharmacol., 195 (1991) 341-345.
7. Hough, L.B., Pearl, S.M. and Glick, S.D., Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration, Life Sci., 58 (1996) PL 119-122.
8. Maisonneuve, I.M., Keller, R.W. and Glick, S.D., Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study, Eur. J. Pharmacol., 199 (1991) 35-42.
9. Maisonneuve, I.M., Rossman, K.L., Keller, R.W. and Glick, S.D., Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res., (1992) 575, 69-73.
10. Mash, D.C., Staley, J.K., Baumann, M.H., Rothman, R.B. and Hearn, W.L., Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin, Life Sci., 57 (1995) PL 45-50.
11. Mash, D.C., Staley, J.K., Pablo, J.P., Holohean, A.M., Hackman, J.C. and Davidoff, R.A., Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex, Neurosci. Lett., 192 (1995) 53-56.
12. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, Orlando, FL, 1986.
13. Pearl, S.M., Herrick-Davis, K., Teitler, M. and Glick, S.D., Radioligand binding study of noribogaine. a likely metabolite of ibogaine, Brain Res., 675 (1995) 342-344.
14. Pearl, S.M., Johnson, D.W. and Glick, S.D., Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation, Psychopharmacology, 121 (1995) 470-475.
15. Popik, P., Layer, R.T., Fossom, L.H., Benveniste, M., Geter-Douglass, B., Witkin, J.M. and Skolnick, P., NMDA antagonist properties of the putative antiaddictive drug, ibogaine, J. Pharmacol. Exp. Ther., 275 (1995) 753-760.
16. Repke, D.B., Artis, D.R., Nelson, J.T. and Wong, E.H.F., Abbreviated ibogaine congeners. Synthesis and reactions of tropan-3-yl-2 and -3-indoles. Investigation of an unusual isomerization of 2-substituted indoles using computational and spectroscopic techniques, J. Org. Chem., 59 (1994) 2164-2171.
17. Sheppard, S.G., A preliminary investigation of ibogaine: case reports and recommendations for further study, J. Sub. Abuse Treat., 11 (1994) 379-385.
18. Simmons, M.L., Terman, G.W., Drake, C.T. and Chavkin, C., Inhibition of glutamate release by presynaptic κ-1-opioid receptors in the guinea pig dentate gyrus, J. Neurophysiol., 72 (1994) 1697-705.
19. Spanagel, R., Herz, A. and Shippenberg, T.S., Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway, Proc. Natl. Acad. Sci. USA, 89 (1992) 2046-2050.
20. Taber, M.T., Das, S. and Fibiger, H.C., Cortical regulation of subcortical dopamine release: mediation via the ventral tegmental area, J. Neurochem., 65 (1995) 1407-1410.
21. Weeks, J.R., Long-term intravenous infusion. In R.D. Myers (Ed.), Methods in Psychobiology, Vol. 2, Academic Press, New York, 1972, pp. 155-168.